Pan-cancer analysis of NFE2L2 mutations identifies a subset of lung cancers with distinct genomic and improved immunotherapy outcomes.
Biomarker
Immunotherapy
NFE2L2
NGS
NSCLC
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
04 Oct 2023
04 Oct 2023
Historique:
received:
26
01
2023
accepted:
06
09
2023
medline:
5
10
2023
pubmed:
5
10
2023
entrez:
4
10
2023
Statut:
epublish
Résumé
Mutations in the KEAP1-NFE2L2 signaling pathway were linked to increased tumorigenesis and aggressiveness. Interestingly, not all hotspot mutations on NFE2L2 were damaging; some even were activating. However, there was conflicting evidence about the association between NFE2L2 mutation and Nrf2-activating mutation and responsiveness to immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) and other multiple cancers. The study with the largest sample size (n = 49,533) explored the landscape of NFE2L2 mutations and their impact response/resistance to ICIs using public cohorts. In addition, the in-house WXPH cohort was used to validate the efficacy of immunotherapy in the NFE2L2 mutated patients with NSCLC. In two pan-cancer cohorts, Nrf2-activating mutation was associated with higher TMB value compared to wild-type. We identified a significant association between Nrf2-activating mutation and shorter overall survival in pan-cancer patients and NSCLC patients but not in those undergoing ICIs treatment. Similar findings were obtained in cancer patients carrying the NFE2L2 mutation. Furthermore, in NSCLC and other cancer cohorts, patients with NFE2L2 mutation demonstrated more objective responses to ICIs than patients with wild type. Our in-house WXPH cohort further confirmed the efficacy of immunotherapy in the NFE2L2 mutated patients with NSCLC. Lastly, decreased inflammatory signaling pathways and immune-depleted immunological microenvironments were enriched in Nrf2-activating mutation patients with NSCLC. Our study found that patients with Nrf2-activating mutation had improved immunotherapy outcomes than patients with wild type in NSCLC and other tumor cohorts, implying that Nrf2-activating mutation defined a distinct subset of pan-cancers and might have implications as a biomarker for guiding ICI treatment, especially NSCLC.
Sections du résumé
BACKGROUND
BACKGROUND
Mutations in the KEAP1-NFE2L2 signaling pathway were linked to increased tumorigenesis and aggressiveness. Interestingly, not all hotspot mutations on NFE2L2 were damaging; some even were activating. However, there was conflicting evidence about the association between NFE2L2 mutation and Nrf2-activating mutation and responsiveness to immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) and other multiple cancers.
METHODS
METHODS
The study with the largest sample size (n = 49,533) explored the landscape of NFE2L2 mutations and their impact response/resistance to ICIs using public cohorts. In addition, the in-house WXPH cohort was used to validate the efficacy of immunotherapy in the NFE2L2 mutated patients with NSCLC.
RESULTS
RESULTS
In two pan-cancer cohorts, Nrf2-activating mutation was associated with higher TMB value compared to wild-type. We identified a significant association between Nrf2-activating mutation and shorter overall survival in pan-cancer patients and NSCLC patients but not in those undergoing ICIs treatment. Similar findings were obtained in cancer patients carrying the NFE2L2 mutation. Furthermore, in NSCLC and other cancer cohorts, patients with NFE2L2 mutation demonstrated more objective responses to ICIs than patients with wild type. Our in-house WXPH cohort further confirmed the efficacy of immunotherapy in the NFE2L2 mutated patients with NSCLC. Lastly, decreased inflammatory signaling pathways and immune-depleted immunological microenvironments were enriched in Nrf2-activating mutation patients with NSCLC.
CONCLUSIONS
CONCLUSIONS
Our study found that patients with Nrf2-activating mutation had improved immunotherapy outcomes than patients with wild type in NSCLC and other tumor cohorts, implying that Nrf2-activating mutation defined a distinct subset of pan-cancers and might have implications as a biomarker for guiding ICI treatment, especially NSCLC.
Identifiants
pubmed: 37794491
doi: 10.1186/s12935-023-03056-9
pii: 10.1186/s12935-023-03056-9
pmc: PMC10552358
doi:
Types de publication
Journal Article
Langues
eng
Pagination
229Subventions
Organisme : top Talent Support Program for young and middle-aged people of Wuxi Commission of Health
ID : HB2020040
Organisme : Mega-project of Wuxi Commission of Health
ID : Z202007
Organisme : Natural Science Foundation of Jiangsu Province
ID : BK20210068
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Cancer Res. 2013 Apr 1;73(7):2199-210
pubmed: 23382044
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Cell Rep. 2016 Sep 6;16(10):2605-2617
pubmed: 27568559
J Immunother Cancer. 2022 Jun;10(6):
pubmed: 35705314
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Mod Pathol. 2022 Jul;35(7):929-937
pubmed: 35194221
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Nat Commun. 2022 Jul 23;13(1):4264
pubmed: 35871175
Nat Rev Mol Cell Biol. 2020 Jul;21(7):363-383
pubmed: 32231263
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
Cell Biosci. 2020 Mar 10;10:31
pubmed: 32175074
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Innovation (Camb). 2021 Jul 01;2(3):100141
pubmed: 34557778
Cancer Cell. 2021 Jun 14;39(6):845-865.e7
pubmed: 34019806
Clin Lung Cancer. 2022 Sep;23(6):487-497
pubmed: 35705448
Cell. 2018 Apr 5;173(2):371-385.e18
pubmed: 29625053
Elife. 2018 Dec 11;7:
pubmed: 30526857
Antioxid Redox Signal. 2006 Jan-Feb;8(1-2):43-52
pubmed: 16487036
Genome Res. 2018 Nov;28(11):1747-1756
pubmed: 30341162
Clin Cancer Res. 2018 Jul 1;24(13):3087-3096
pubmed: 29615460
Clin Cancer Res. 2021 Jan 1;27(1):202-212
pubmed: 33020056
Nat Genet. 2018 Sep;50(9):1271-1281
pubmed: 30150660
Eur Urol. 2020 Nov;78(5):671-679
pubmed: 32317181
J Thorac Oncol. 2020 Jun;15(6):e85-e86
pubmed: 32471565
Redox Biol. 2018 Jul;17:297-314
pubmed: 29775961
Antioxid Redox Signal. 2015 Apr 20;22(12):965-76
pubmed: 25556935
Am J Ther. 2010 Sep-Oct;17(5):e137-62
pubmed: 19433977
Cancer Cell. 2019 Feb 11;35(2):238-255.e6
pubmed: 30753825
J Thorac Oncol. 2021 Aug;16(8):1392-1402
pubmed: 33992811
Free Radic Biol Med. 2020 Sep;157:63-74
pubmed: 32234331
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Oncologist. 2020 Jun;25(6):e955-e963
pubmed: 32272498
Autophagy. 2022 Aug;18(8):2013-2015
pubmed: 35438056
Immunity. 2020 Jan 14;52(1):17-35
pubmed: 31940268
Nat Genet. 2022 Jul;54(7):996-1012
pubmed: 35817971
J Adv Res. 2023 Sep;51:121-134
pubmed: 36351537
Annu Rev Pharmacol Toxicol. 2013;53:401-26
pubmed: 23294312
Cancers (Basel). 2020 Dec 21;12(12):
pubmed: 33371179
Oxid Med Cell Longev. 2020 Oct 9;2020:3580719
pubmed: 33101586
Hepatology. 2021 Aug;74(2):741-759
pubmed: 33529367
JAMA Netw Open. 2019 Sep 4;2(9):e1911895
pubmed: 31539077
BMC Bioinformatics. 2022 May 31;23(1):205
pubmed: 35641905
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
Cancers (Basel). 2022 Jul 12;14(14):
pubmed: 35884443
NPJ Precis Oncol. 2021 May 4;5(1):36
pubmed: 33947957
Cell Res. 2020 Oct;30(10):902-913
pubmed: 32398863
J Pathol. 2020 Oct;252(2):125-137
pubmed: 32619021
Lung Cancer. 2021 Sep;159:10-17
pubmed: 34303275
J Thorac Oncol. 2023 Apr;18(4):516-526
pubmed: 36240971
J Thorac Oncol. 2021 Mar;16(3):395-403
pubmed: 33307193
Nat Genet. 2021 Jan;53(1):11-15
pubmed: 33398197
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Cancer Cell. 2018 May 14;33(5):843-852.e4
pubmed: 29657128
J Thorac Oncol. 2021 Dec;16(12):2065-2077
pubmed: 34450259
Cell. 2022 Feb 3;185(3):563-575.e11
pubmed: 35120664
Nat Commun. 2017 Oct 10;8(1):818
pubmed: 29018201
J Immunother Cancer. 2021 Aug;9(8):
pubmed: 34376553
N Engl J Med. 2022 Jun 2;386(22):2112-2119
pubmed: 35648703
Immunity. 2019 Aug 20;51(2):411-412
pubmed: 31433971
Genome Biol. 2017 Nov 15;18(1):220
pubmed: 29141660
JAMA Netw Open. 2020 Aug 3;3(8):e2013201
pubmed: 32845327
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Ann Oncol. 2020 Dec;31(12):1746-1754
pubmed: 32866624
JAMA Oncol. 2022 Aug 1;8(8):1160-1168
pubmed: 35708671
NPJ Precis Oncol. 2022 Jan 18;6(1):4
pubmed: 35042953
Nat Med. 2018 Oct;24(10):1545-1549
pubmed: 30127394